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RNA binding proteinThe deletion of ORF11 severely impaired VZV infection of human skin xenografts. Here, we investigate the
characteristics and functions of the ORF11 gene product. ORF11 is expressed as a 118 kDa polypeptide in VZV-
infected cells; the protein is present in the nucleus and cytoplasm and is incorporated into VZ virions.
Although ORF11 had little effect in transactivating VZV gene promoters in transfection assays, deleting ORF11
from the virus was associated with reduced expression of immediate early proteins IE4, IE62 and IE63, and the
major glycoprotein, gE. ORF11 was identiﬁed as an RNA binding protein and its RNA binding domain was
deﬁned. However, disrupting the ORF11 RNA binding domain did not affect skin infection, indicating that RNA
binding capacity, conserved among the alphahepesviruses homologues, is not essential while the contribution
of ORF11 to the expression of the IE proteins and gE may be required for VZV pathogenesis in skin in vivo., Stanford University School of
25 9828.
l rights reserved.© 2011 Elsevier Inc. All rights reserved.Introduction
Varicella zoster virus (VZV) open reading frame 11 (ORF11) is one of
a conserved gene cluster found in the alphaherpesviruses that includes
VZV ORF9-ORF12 (Che et al., 2008; Cohen et al., 2007; Davison, 1991;
Davison and Scott, 1986). The protein encoded by VZV ORF11 is
presumed to be a tegument component but its gene product and
functional characteristics have not been described. We reported
recently that a VZV recombinant lacking ORF11 (POKAΔ11) replicates
like the parent virus (POKA) in cultured cells, as didmutants fromwhich
ORF10 andORF12hadbeendeleted (Che et al., 2008; Zhang et al., 2010).
These studies suggested that ORF11 and its ﬂanking genes are not
critical in vitro. However, a hierarchy of effects was observed when
thesemutantswere evaluated for virulence in human skin xenografts in
SCID mice. Deleting ORF12 did not alter VZV pathogenesis in skin
whereas deleting ORF10 was associated with a 10-fold decrease in
infectious virus yields and the ORF11-null virus had evenmore severely
impaired infectivity, replicating 500-fold less efﬁciently than POKA (Che
et al., 2006, 2008; Zhang et al., 2010). Furthermore, the effect of dual
deletions of bothORF10 andORF11 (POKAΔ10/11) or ORF11 andORF12
(POKAΔ11/12) was similar to the consequences of removing only
ORF11. Thus, although ORF11 functions were not deﬁned in these
experiments, ORF11 was identiﬁed as a major VZV virulence determi-
nant in differentiated epidermal cells in their tissue microenvironment
in vivo.VZV ORF11 is homologous to the UL47 of other alphaherpesviruses
(Kinchington and Cohen, 2000; Roizman and Campadelli-Fiume, 2007).
Removing UL47 from herpes simplex virus type 1 (HSV-1) is associated
with diminished expression of IE proteins and the HSV-1 UL47-null
mutant replicated more slowly than wild-type virus in cultured cells,
indicating a regulatory role for UL47 in gene expression early in the
infectious cycle (Zhang et al., 1991; Zhang and Mcknight, 1993).
Moreover, replication of pseudorabies virus (PRV) and Marek's disease
virus (MDV) mutants that lack UL47 was also delayed compared to
wild-type viruses in cell culture (Dorange et al., 2002; Kopp et al., 2002).
Recent studies revealed that HSV-1 UL47 binds to RNA and has the
capacity to shuttle between the nucleus and the cytoplasm during
infection, suggesting that the UL47 gene product may be involved in
RNA biogenesis during viral infection (Donnelly and Elliott, 2001a,
2001b; Donnelly et al., 2007; Verhagen et al., 2006a). Subsequently,
studies of the bovine herpesvirus type 1 (BHV-1) homolog demonstrat-
ed that it also binds to RNA and shuttles between the nucleus and the
cytoplasm (Carpenter and Misra, 1991; Donnelly and Elliott, 2001a;
Verhagen et al., 2006b). Most recently, Dobrikova and coworkers have
shown that HSV-1 UL47, via interactionwith ICP27, another HSV-1 RNA
binding protein, exists in a complex with cytoplasmic polyadenylate-
binding protein (PABP) (Dobrikova et al., 2010). Further investigation
showed that ICP27 and UL47 did not alter the translation efﬁciency of
transfected reporter RNAs but modulated transcript abundance of
reporter cDNAs in transfected cells, implying that ICP27 and UL47 may
regulate viral or host gene expression in the steps of mRNA processing
and/or export rather than translation initiation.
While these ORF11 homologues have been identiﬁed as RNA
binding proteins and are implicated in functions related to viral or
cellular RNA processes, it has not been determined whether their RNA
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speciﬁc RNA binding motif in the protein and examining effects of
disrupting the coding sequence for the motif in the viral genome on
replication. The present study was designed to investigate the
characteristics and functions of the ORF11 gene product and when
ORF11 was identiﬁed as an RNA binding protein, to investigate the
effects of mutations that disrupted this function in vitro and in human
skin xenografts in SCID mice in vivo.
Results
Identiﬁcation of the ORF11 gene product
ORF11 expressed as a GST fusion protein was used to generate a
rabbit polyclonal antiserum, designated Ab11. POKA-infected cell
lysates were prepared 48 h after infection. When this antiserum was
used for Western blot to test infected cell lysates, a single 118kDa
protein was detected in lysates from POKA-infected cells but not in
lysates from mock-infected cells or in those from cells infected with
four ORF11 deletion mutants, POKAΔ11, POKAΔ10/11, POKAΔ11/12,
and POKAΔ10/11/12. The IE4 protein, used as a positive control, was
detected at similar levels in lysates of cells infectedwith POKA and the
ORF11 deletion mutants (Fig. 1A).
To investigate the products of ORF11 expressed in the absence of
other viral proteins, cell lysates were extracted from melanoma cells
after transfection with the ORF11 expression vector pCMV11 and
analyzed by Western blot using Ab11. One product migrating at
118 kDa was identical to the species detected in VZV-infected cell
lysates, whereas a second species of 114 kDa was produced with
transient expression of ORF11 (Fig. 1B).
ORF11 protein distributes to the nuclei and cytoplasm of infected cells
To determine the distribution of ORF11 during viral infection, the
infected cells were fractionated to make nuclear and cytoplasmic
extracts.When cell fractionswere analyzed byWestern blot with Ab11,
ORF11 was present in both the nuclear and cytoplasmic fractions of
infected cells but not in uninfected cell fractions (Fig. 2A). To ensure the
purity of the fractionations, the samemembrane probed for ORF11 was
then stripped and re-probed for IE62,α-tubulin and RCC1 (regulator of
chromosome condensation 1). IE62 was predominantly in the nuclear
fraction, the nuclear protein RCC1was only detected in the nuclear
fraction and α-tubulin remained in the cytoplasmic fraction (Fig. 2A).
These data indicate that effective separation was achieved during
fractionation.Fig. 1. ORF11 is expressed as one product in infected cells but as two products in
transfected cells. (A) Western blot of total cell lysates extracted from melanoma cells
either mock infected or infected with POKA or ORF11 deletion mutants with antibodies
to ORF11 (Ab11) or IE4. IE4 was used as a loading control. (B) Western blot for
detecting ORF11 from POKA and mock infected or from pCMV11 and pcDNA3.1
transfected melanoma cells with Ab11 antibody. Arrowheads indicate two products of
118 and 114 kDa observed from ORF11 transfected cells. Molecular masses of the
protein marker (kDa) are indicated between two blots.The intracellular localization of ORF11 protein in infected cells was
further examinedbyconfocalmicroscopy. InfectedHELF cellswereﬁxed
at10or24 hafter infection andevaluated forORF11distribution relative
to the localization of VZV IE62 and gE. UninfectedHELF cells were tested
with Ab11 and IE62 antibody showed no staining (Fig. 2B, panel I); in
infected cells tested with the Ab11 preimmune serum together with
IE62 antibody, IE62 was detected but no ORF11 signal was observed
(Fig. 2B, panel II). When infected cells ﬁxed at 10 h after VZV infection
were co-stainedwithORF11 and IE62antibodies, ORF11was detected in
thenucleus and cytoplasm in cells that expressed IE62(Fig. 2B,panel III).
Infected cells ﬁxed at 24 h post infection had extensive syncytium
formation; when these cells were co-stained with Ab11 and a gE
antibody, gE was present in a diffuse cytoplasmic distribution, while
ORF11 expression was observed in both the nuclei and cytoplasm of gE
positive cells; ORF11 was not detectable in cells that had no gE
expression (Fig. 2C). These observations were consistent with the
Western blot analysis (Fig. 2A), which showed that ORF11 protein was
present in both nuclear and cytoplasmic fractions of VZV-infected cells.
In addition, when cells were transfected with pCMV11 and ﬁxed after
48 h, ORF11 protein had a diffuse distribution in the nucleus and
cytoplasm (Fig. 2D), whichwas similar to that observed in VZV-infected
cells.
ORF11 protein is a component of the VZ virion tegument
To achieve highly sensitive and speciﬁc immunogold-labeling in
combination with ultrastructural resolution, POKA-infected cells were
analyzed by cryo-immuno EM. Using Ab11 antibody together with
Protein A conjugated to 15 nm gold particles, we detected dense and
speciﬁc ORF11 labeling within the tegument of VZ virions, indicating
that ORF11 protein was incorporated into VZV particles as a component
of the tegument (Fig. 3A). The control experiment inwhich cryosections
of the same infected sample were incubated with Ab11 preimmune
serum, showed no gold-labeling, indicating the speciﬁcity of the Ab11
antibody in immune-EM assays (Fig. 3B).
The effect of ORF11 on VZV gene expression
To determine whether ORF11, as a VZV tegument protein, might
contribute to the regulation of VZV gene expression, the effect of ORF11
on promoters of VZV genes was evaluated in transient transfection
assays using promoter constructs and the expression of IE or late VZV
proteins was assessed in cells infected with a recombinant VZV lacking
ORF11.
In transient expression assays, melanoma cells were transfected
with three luciferase reporter plasmids that had promoters of VZV gene
products including ORF61, ORF10 and gE. When the promoter
constructs and pGL3 control vector were individually transfected,
Renilla luciferase readings with those promoter constructs was low
and similar to that with the pGL3 vector (data not shown). However,
when IE62 was expressed with the reporter plasmids, luciferase
expression fromeachof thepromoter constructs increased signiﬁcantly,
to about 300-fold (ORF61), 250-fold (ORF10), and 420-fold (gE) above
the promoter-less control, respectively (Fig. 4A). These results were
consistent with previous reports that IE62 alone strongly transactivates
all three promoters, although with different efﬁciencies (Berarducci
et al., 2007; Che et al., 2007; Ruyechan et al., 2003; Wang, et al., 2009;
Yang et al., 2006). In contrast, luciferase expressionwas similar or about
2-fold higher as compared to the promoter-less control when pCMV11
was co-transfectedwith the construct in which luciferase reporter gene
expression was regulated by the ORF61, ORF10 or the gE promoter.
Thus, little or no regulatory effect of ORF11 on these promoters was
detected in transient transfection assays.
To further investigate whether ORF11might contribute to VZV gene
expression at the protein level under conditions of viral replication,
melanoma cells were infected with POKA or the deletion mutant,
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Fig. 3. Virion localization of ORF11 protein. Cryo-immuno EM of VZV-infected melanoma cells. Cells were ﬁxed, embedded, and sectioned 48 h after VZV infection and then incubated
with Ab11 (panel A) or Ab11 preimmune serum (panel B) followed by incubation with protein A gold conjugate and examined by EM. ORF11 (15-nm gold particles) is incorporated
into VZV virions and present in the virion tegument (panel A). Size bars: panels A and B, 0.2 μm.
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detect IE4, IE62, IE63 and gE over a 4-day time course as shown in a
representative analysis in Fig. 4B. At day 1 post-infection, a signiﬁcant
reduction in the levels of IE62 and IE4 was observed in cells infected
with POKAΔ11 compared to POKA. By day 2 post-infection, IE4 reached
levels similar to those in POKA-infected cells.While IE62 expression had
increased substantially byday2, it continued to remain lowcompared to
POKA-infected cells over the 4-day interval. IE63 production in cells
infected with POKAΔ11 was substantially delayed compared to POKA,
showing diminished expression for the ﬁrst 3 days after infection
(Fig. 4B). In addition, a very small amount of gE protein was detected in
POKA-infected cells at day 1 but not in POKAΔ11-infected cells and
levels of gE expression in cells infected with POKAΔ11 remained
reduced over the 4-day period in comparison to POKA (Fig. 4B). Thus,
ORF11 was required for normal levels of VZV IE4, IE62, IE63 and gE
proteins in cultured cells in vitro, with the most substantial delays
associated with IE63 and gE expression.ORF11 binding to RNA in VZV-infected cells
To assess whether ORF11 protein binds to viral RNA, ORF11 protein
was ﬁrst immunoprecipitated frommelanoma cells infected with POKA
using Ab11. IE63mRNA is abundant during VZV infection and therefore
was chosen to screen for possible ORF11 protein binding to viral RNAs.
Co-immunoprecipitated RNAwas reverse transcribed and the 3' portion
of the IE63 RNAwasdetected byPCR. The single PCRproduct,whichwas
identiﬁed as IE63 by sequencing from the nucleotide 349 to the
polyadenylation site, was observed by agarose gel electrophoresis from
the infected cell sample immunoprecipitatedwith Ab11 butwas absent
when Ab11 was not included (Fig. 5A). Immunoprecipitation was also
done with a polyclonal antibody against ORF47, another VZV tegument
protein, which can be used in both Western blot and immunoprecip-
itation experiments (Besser et al., 2003); IE63 mRNA was not detected
in the complex immunoprecipitated with or without anti-ORF47
antibody (Fig. 5A). No RT-PCR product was synthesized from the
mock-infected cell sample when it was immunoprecipitated with Ab11
or in the absence of the antibody (Fig. 5A). Furthermore, when infected
cells were used for RNA immunoprecipitation with the Ab11 pre-Fig. 2. The intracellular localization of ORF11 during VZV infection. (A) Western blots of t
prepared frommelanoma cells at 48 h post-infection with POKA. The samemembrane was pr
protein and two cellular proteins, α-tubulin (cytoplasmic marker) and RCC1 (nuclear mark
Ab11 and anti-IE62 antibody; panel II: Infected HELF stained with antibodies to IE62 and
infection. Cells were stained together with antibodies to IE62 and ORF11 and then were
conjugated secondary antibodies. Representative infected cell indicated that ORF11 distribu
antibodies against gE (red) and ORF11 (green). Cell nuclei were counterstained with Hoech
transfected cells. Melanoma cells were transfected with ORF11-expressing plasmid (pCMV1immune serum, no IE63 PCR product was observed (data not shown).
These results suggested that ORF11 and/or a complex that contains
ORF11 can bind to RNA in VZV-infected cells.
Requirement of the ORF11 N-terminus for its RNA binding activity
To determine whether ORF11 has the capacity to bind to RNA
directly, in the absence of other viral proteins, we used an expression
system to make puriﬁed ORF11 recombinant protein. The ORF11 gene
was initially fused to GST and expressed in E. coli, but full-length ORF11
protein could not be recovered. Therefore we generated constructs that
expressed the N-terminal 261 residues and C-terminal 233 residues of
ORF11, each including about one third of the ORF11 gene, fused to GST.
Samples of IPTG induced and non-induced cell lysates were separated
on SDS-PAGE followed by Coomassie blue stain or Northwestern blot
with an in vitro synthesized IE63 RNA probe that contained +71 to
+602 of IE63 mRNA (Fig. 5B). The Coomassie blue stain showed that
GST and GST fusion proteins were expressed (Fig. 5B) and the
Northwestern blot indicated that the recombinant GST-tagged ORF11
N-terminal truncation (ORF11N) bound to the IE63 RNA probe, while
GST alone and the GST-tagged ORF11 C-terminal truncation (ORF11C)
did not (Fig. 5B). Several additional indistinct bands were also detected
by Northwestern blot, but the bands were present in all samples,
indicating that they were non-speciﬁc. Thus the ORF11 N-terminus but
not the C-terminal region has efﬁcient RNA binding activity when
expressed in the absence of virus infection.
Mapping the RNA binding domain of ORF11 protein
To determine regions of the ORF11 N-terminus that were involved
in RNA binding, a series of ORF11 N-terminal truncation mutations
fused to GST was generated [Fig. 5C(a)]. Two large ORF11 N-terminal
mutants that eliminated residues 1–115 or residues 1–190 [Fig. 5C(a),
2 and 3] exhibited no RNA binding activity [Fig. 5C(b), lanes 2 and 3],
whereas the truncation mutation that lacked residues 123–261 and
the ORF11 N-terminal 261 residues [Fig. 5C(a), 5 and 7] bound
efﬁciently to the IE63 RNA probe [Fig. 5C(b), lanes 5 and 7). These
results indicated that the ORF11 RNA binding properties were locatedhe ORF11 detection in nuclear and cytoplasmic fractions. Cellular fractionations were
obed for ORF11 then stripped and re-probed for VZV IE62, a predominantly nuclear viral
er) to determine the purity of the fractions. (B) Panel I: Uninfected HELF stained with
Ab11 preimmune serum; panel III: Confocal microscopy of HELF cells ﬁxed 10 h post-
co-stained with Texas Red (IE62, red) and ﬂuorescein isothiocyanate (ORF11, green)
ted both in nucleus and cytoplasm. (C) HELF cells were ﬁxed 24 hpi and stained with
st 22358 (blue). Size bars: 10 μm. (D) Confocal images of ORF11 protein distribution in
1), ﬁxed at 48 hpi, and stained with Ab11 (green).
Fig. 4. Effect of ORF11 on VZV gene expression. (A) In vitro luciferase assays. Melanoma
cellswere transfectedwith luciferase reporter constructs containing promoters for ORF61,
ORF10, ORF68 (gE) or the control construct (pGL3) together with plasmids pCMV11 or
pCMV62. The luciferase assays were done using cells collected 24 h after transfection. The
bars indicated the mean ± standard deviation of two independent transfection
experiments in which each combination of reporter construct/VZV gene was tested in
triplicate. (B)Western blot for detecting IE62, IE4, IE63 and gE proteins from cells infected
either by wild-type POKA or ORF11 deletion mutant (POKAΔ11). Cell extracts were
collected over a time course of 1, 2, 3 and 4 days post-infection and used for Western blot
analysis with rabbit polyclonal antibodies against IE4, IE62, and IE63 or with mouse
monoclonal antibodies against gE and α-tubulin, respectively. Samples tested including
POKA and POKAΔ11 (Δ11) and the time after inoculation are indicated above the blots.
Proteins examined are listed on the left; α-tubulin served as a loading control.
160 X. Che et al. / Virology 412 (2011) 156–166within the ﬁrst 1–122 residues of the protein. Deletion of the ﬁrst
15 residues from the constructs containing ORF11 N-terminal 1–122
or 1–261 residues [Fig. 5C(a), 1 and 6) resulted in ORF11 mutant
proteins that lacked RNA binding activity (Fig. 5C(b), lanes 1 and 6). In
contrast, ORF11 truncated protein consisting of the ﬁrst 22 residues of
the N-terminus fused to GST [Fig. 5C(a), 4] retained the capacity to
bind to IE63 transcripts as effectively as the longer ORF11 peptides
[Fig. 5C(b), lane 4]. These results suggested that the ﬁrst 22 residues of
ORF11 contained an RNA binding domain.
Binding of the VZV ORF11 N-terminus to viral or cellular genes transcripts
To investigate whether the ORF11 RNA binding domain interacted
with RNAs of other VZV genes, RNA probes corresponding to VZV IE,
early and late genes transcripts, including ORF61 (+17 to +825),
IE62 (+23 to +813), ORF29 (−50 to +771) and gE (−29 to +699)
were used for Northwestern analysis. The α-actin RNA probe of about
700 nts was also included. In these experiments, equal amounts of the
ORF11 N-terminal 1–261-GST fusion protein or GST, as shown by
Coomassie blue stain, were hybridized with in vitro synthesized RNA
probes (Fig. 5D). All probes showed binding to the ORF11 N-terminus.
Thus, the ORF11 N-terminal domain bound non-selectively to
transcripts corresponding to VZV IE, early and late genes and the
cellular actin gene in the in vitro RNA binding assays.An arginine-rich motif is essential for ORF11 RNA binding activity
Two ORF11 expression constructs, pORF11N/ST1-GST and
pORF11N/ST2-GST, were made to investigate whether the arginine
residues of the arginine-rich box located at ORF11 N-terminal
residues 8–15 were required for the ORF11 RNA binding function
[Fig. 5E(a)]. These alanine substitution mutants were expressed in E.
coli and puriﬁed proteins with the same loading amounts shown by
Coomassie blue stain were used for Northwestern blot with the IE63
RNA probe [Fig. 5E(b)]. Substitution of all ﬁve arginine residues in the
arginine-richmotif inhibited RNA binding, shown by comparison with
the GST control; the replacement of the ﬁrst two arginines with
alanine residues decreased RNA binding activity signiﬁcantly com-
pared to the non-mutated construct, but some residual RNA binding
was observed [Fig. 5E(b)]. Thus, the arginine-richmotif locatedwithin
the ﬁrst 15 residues of ORF11 N-terminus is necessary for its RNA
binding and the ﬁrst two arginine residues in the motif are required
for optimal ORF11 RNA binding function.
Effects of mutating the ORF11 N-terminus and the RNA binding motif in
the VZV genome in vitro
Based on these observations using ORF11 N-terminal expression
constructs, two VZV recombinants were generated. In POKA11-Nd,
the ORF11 RNA binding domain was deleted and in POKA11-Ns,
alanines were substituted for arginine residues within the RNA
binding motif (Fig. 6A). The deletion of the ORF11 N-terminus and the
presence of the targeted mutations in these VZV recombinants were
conﬁrmed by DNA sequencing. Sequencing also showed that the
lengths of the ORF11 repeat region, designated R1 in the VZV genome
(Davison and Scott, 1986), differed between POKA, POKA11-Nd and
POKA11-Ns. Since the R1 region of the cosmid used as a template for
generating VZV recombinants was same as that of POKA, the
variations of the R1 in POKA11-Nd and POKA11-Ns appear to result
from the mutagenesis process. These results conﬁrm an early study
showing that VZV repeat regions were difﬁcult to clone and that the
size of the reiterations often differed from the template (Davison and
Scott, 1986). R1 consists of multiples of 3 bp that encode repeated
amino acid sequences. The DNA sequences were converted to the
corresponding amino acids and the repeated sequences are grouped
as A, B and C, based on their amino acid composition; the A sequence
is DAIDDE, the B residues are GEAEE; the C sequence is DAAEE, which
is a partial copy of A and B, consisting of the ﬁrst two-amino acid of A
linked to the last three-amino acids of B. The ORF11 reiteration in
POKA contained 75 amino acids with ﬁve A repeats, eight B repeats
and one C repeat; the ORF11-Nd reiteration had an additional A and B
repeat not present in POKA ORF11 and was 86 amino acids; ORF11-Ns
had the shortest reiteration, consisting of 27 amino acids with two A
repeats and three B repeats (Fig. 6B).
Western blots were performed to examine whether deleting or
mutating the ORF11 RNA binding domain or these variations in the
length of the repeat regions affected the synthesis and cellular
distribution of the ORF11 protein. Analysis of melanoma cells infected
with POKA, POKA11-Nd, and POKA11-Ns showed that ORF11-Ns and
ORF11-Nd, like ORF11, were expressed and present in both the
nuclear and cytoplasmic fractions of infected cell lysates (Fig. 6C). The
apparent reduction in ORF11-Ns and ORF11-Nd levels in the Western
blot was probably due to decreased antibody binding afﬁnity because
the antibody was generated using an ORF11 N-terminal peptide;
alternatively the mutated proteins may be less stable and the
differences in the repeat regions could cause the lower binding
afﬁnity. The molecular masses of POKA ORF11, ORF11-Ns and ORF11-
Nd were about 118, 110 and 104 kDa, respectively, which was
consistent with sizes of 794 amino acids for ORF11, 746 amino acids
for ORF11-Ns, and 703 amino acids for ORF11-Nd, based on the
corresponding DNA sequencing results.
Fig. 5. ORF11 is a RNA binding protein. (A) ORF11 binding to IE63 mRNA in VZV-infected cells. Melanoma cells were collected 24 h after infection with POKA or mock infection.
Immunoprecipitation of total cell extracts was done in the presence of Ab11 or anti-ORF47 antibody (Ab+) or without antibody (Ab−). Nucleic acid was extracted from the
immunoprecipitation samples and subjected to RT-PCRwith primers designed to amplify ORF63mRNA; one ﬁfth of each PCR reaction was analyzed by agarose gel electrophoresis in
the presence of ethidium bromide. The molecular masses are shown on the left (M). (B) ORF11 N-terminus but not its C-terminus exhibited the RNA binding capacity. The N- and C-
terminal regions of ORF11 were expressed as GST fusion proteins. IPTG induced (I) and uninduced (U) bacteria cell lysates were separated by SDS-PAGE followed by Coomassie blue
stain or Northwestern blotting with an in vitro synthesized IE63 RNA probe. Coomassie blue stain showed induction of the expression of GST fused to the ORF11 N-terminus
(ORF11N) or the ORF11 C-terminus (ORF11C), and GST by IPTG as indicated by white arrows. In the Northwestern blot, the signal of ORF11-RNA interaction was only observed with
the ORF11N (lane 4 pointed by arrow). The positions of non-speciﬁc binds are indicated by arrowheads. (C) The ﬁrst 22 residues of ORF11 is critical for its RNA binding activity.
(a) Diagrammatic representation of GST-fused ORF11 N-terminal truncation mutations. Filled and open boxes represent the fragment of the ORF11 N-terminal regions and GST,
respectively. The gaps connected with dashed lines indicate deletions. The locations of the ORF11 N-terminal residues fused to GST are noted on the right. (b) Coomassie blue stain of
GST alone and the ORF11 N-terminal GST fusion proteins puriﬁed from E. coli (left panel) and Northwestern blot with an in vitro synthesized IE63 RNA probe (right panel). Proteins of
GST-fused to residues 1–22, 1–122, and 1–261, respectively (Coomassie blue stain, arrows), bound to the RNA probe (Northwestern, arrows). Molecular mass of the protein makers
in kilodalton (kDa) are shown on the left. (D) Northwestern blots of ORF11 N-terminal binding to RNA probes of ORF61, IE62, IE63 and gE or α-actin. Puriﬁed GST alone and the
ORF11 N-terminal (ORF11N) GST fusion protein (residues 1–261) were used for this experiment. Similar amounts of puriﬁed ORF11N (lane 1) together with GST protein (lane 2)
indicated by Coomassie blue stain (left) were used for Northwestern. Probes were listed at the top andmolecular masses of the protein marker (kDa) are indicated on the left. (E) An
arginine-rich box located within the ﬁrst 15 residues of ORF11 is essential for ORF11 RNA binding function. (a) The ﬁrst 29 amino acids of the ORF11 N-terminal 1–122 region is
shown (WT) along with the arginine-rich motif substitution 1 (ST1) and arginine-rich motif substitution 2 (ST2). The arginine-rich motif located at residues 8–15 is underlined. The
ST1 replaced all ﬁve arginines in the arginine-rich motif with alanines and the ST2 substituted the ﬁrst two arginines with alanines. Dots in ST1 and ST2 indicate the unchanged
amino acids. The WT, ST1 and ST2 residues were expressed as GST fusion proteins. (b) Coomassie blue stain (left panel) indicated approximately similar amounts of each GST fusion
protein were used for Northwesternwith the IE63 RNA probe (right panel). ST1 failed to bind to IE63 RNA probe while ST2 retained a very low level of RNA binding activity compared
to the intact ORF11 N-terminal 122 residues (arrowhead).
161X. Che et al. / Virology 412 (2011) 156–166The replication kinetics of POKA11-Nd and POKA11-Ns were next
compared to POKA and POKAΔ11. In a 6-day infectious focus assay,
the replication of POKAΔ11, POKA11-Nd and POKA11-Ns mutants
showed growth kinetics that were similar to POKA (Fig. 7A). In
addition, Western blot assays were performed to investigate the
expression of IE (IE62) and late (gE) genes in lysates from POKA11-Nd
and POKA11-Ns infected cells over a 4-day time course. IE62 and gE
expression did not differ between POKA11-Nd, POKA11-Ns and
POKA-infected cells (data not shown). Thus, neither the targetedmutations in the RNA binding domain nor the variations in the ORF11
reiterations altered VZV replication in cultured cells in vitro.
Effects of mutating the ORF11 N-terminus and the RNA binding motif in
the VZV genome in skin xenografts in vivo
To investigate the effect of deleting or disrupting the ORF11 RNA
binding domain on VZV replication in vivo, skin xenografts were
inoculatedwith ﬁbroblasts infected with POKA, POKA11-Nd, POKA11-
Fig. 7. Replication of POKA, POKAΔ11, POKA11-Nd and POKA11-Ns in melanoma cells in
vitro and in human skin xenografts in vivo. (A) Replication of POKA, POKAΔ11, POKA11-
Nd, and POKA11-Ns in vitro. Melanoma cells were infected with POKA or the ORF11
mutants and tested for replication in a 6-day assay; virus titers were determined by
infectious focus assay. (B) Replication of POKA, POKAΔ11, POKA11-Nd, and POKA11-Ns in
vivo. Skin xenografts were infected with POKA, POKAΔ11, POKA11-Nd, and POKA11-Ns
and harvested at 10 and 21 days after inoculation; virus yields from each sample were
determined by infectious focus assay. No virus (indicated by “x”) was recovered from skin
implants infected with POKAΔ11 either at 10 days or 21 days post-infection. Each bar
represents the mean viral titer (log10), and error bars represent the standard deviations.
Inoculums’ titers of the viruses tested were not signiﬁcantly different.
Fig. 6. Characterization of the VZV recombinant viruses, POKA11-Nd and POKA11-Ns.
(A) Schematic representation of POKA, POKA11-Nd and POKA11-Ns. Filled boxes
represent the segment of the VZV genome up- or downstream of the ORF11 gene,
which is shown as open boxes. The gaps connected with dashes represent the ORF11 N-
terminal deletion, and the designations for the recombinant viruses are given at the left.
The arginine-rich box, its location and substitutions are indicated by arrows. The genomic
location of ORF11 is shown at the top. (B) Amino acid sequences corresponding to the
reiteration regions of POKA ORF11, ORF11-Nd and ORF11-Ns. The amino acid sequences
were grouped as A, B and C, as shown in parentheses. The number of repeats for each
sequence is shown by the subscript, and the genomic location of the repeat region of
ORF11, ORF11-Nd and ORF11-Ns are also indicated. (C) Western blot to show the
expression and distribution of ORF11, ORF11-Ns and ORF11-Nd protein in infected cells
(upper panel). Melanoma cells infected with POKA, POKA11-Ns or POKA11-Nd were
harvested 48 h post-infection and separated into cytoplasmic (Cyto-) or nuclear (Nu-)
fractions. Similar amounts of the two fractions of infected cell lysates were subjected to
SDS-PAGE followedbyWestern blot usingAb11. Lowerpanel: the blotwas re-probedwith
a mouse monoclonal anti-α-tubulin antibody as a cytoplasmic protein marker.
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21 days after infection, and virus yields were determined by an
infectious center assay. No signiﬁcant differences were observed
between the replication of POKA11-Nd and POKA11-Ns and POKA at
either 10 or 21 days post-infection (Pb0.01). As was observed in vitro,
the targeted mutations and the accompanying differences in the
ORF11 reiterations did not affect VZV growth in skin. In contrast,
infectious virus was not recovered from any xenografts inoculated
with POKAΔ11 (Fig. 7B).Discussion
VZV that lacks ORF11 is severely impaired for growth in human skin
xenografts in the SCID mouse model (Che et al., 2008). In these
experiments, we demonstrate that ORF11, a predicted tegument
protein, is incorporated into the virion tegument and is therefore
expected to be released when VZV enter cells.When expressed alone in
transfected cells, ORF11encodes twoproductswith sizes of 118 kDa and
114 kDa. Interestingly, ORF11 is expressed as one 118 kDa product in
infected cells. Theseﬁndings suggest the synthesis of the114 kDaORF11
gene product or its stability are diminished during viral infection.
ORF11 protein exhibited a diffuse nuclear and cytoplasmic distribu-
tion during VZV infection. As infection progressed, the concentration of
ORF11 protein increased, but the pattern of ORF11 expression in both
the nucleus and cytoplasm remains unchanged. In addition, the
distribution of ORF11 protein when expressed alone was similar to its
localization in infected cells. VZVORF11belongs to theherpesvirusUL47
gene family (Davison, 1991; Davison and Scott, 1986; McGeoch et al.,
1988; McLean et al., 1990; Meredith et al., 1991; Roizman and
Campadelli-Fiume, 2007). HSV-1 UL47 is targeted predominantly to
the nuclei of infected cells whether expressed as a green ﬂuorescent
protein (GFP)-tagged protein in a plasmid construct or in cells infected
163X. Che et al. / Virology 412 (2011) 156–166with an HSV-1 recombinant expressing a GFP-tagged UL47 protein
(Donnelly and Elliott, 2001b). We used cell-associated virus for VZV
infection, while cell-free virus was used in the HSV-1 experiments.
However, since this difference in cellular distribution between ORF11
andHSV-UL47wasalso evident in the transfected cells, it seemsunlikely
that the type of inoculum affected the observations in infected cells.
Thus, ORF11 intracellular localization and trafﬁcking differ from that of
its HSV-1 UL47 homolog in both infected and transfected cells.
Although the replication kinetics of the VZV recombinant with the
ORF11 deletion was similar to that of wild-type POKA in tissue culture
(Che et al., 2008; Zhang et al., 2010), we found that the synthesis of
IE4, IE62, IE63 and gE proteins in POKAΔ11-infected cells was delayed
or reduced compared to POKA-infected cells. Signiﬁcant reductions of
IE62 and IE4 proteins were evident in POKAΔ11-infected cells at 24 h
after inoculation but IE4 levels were similar to those in POKA-infected
cells by 48 h and IE62 levels had increased substantially. In contrast,
we noted that the pattern of gene expression observed in cells
infected with the two RNA binding mutants, POKA11-Nd and
POKA11-Ns, was indistinguishable from POKA over a 4-day time
course. The observations with POKAΔ11 suggest that the lower levels
of expression of essential regulatory proteins that occur in the absence
of ORF11 at early times after VZV infection are tolerated and that
expression of major IE gene products recovers rapidly, allowing
normal replication of the ORF11 null mutant in vitro. Furthermore, we
showed that ORF11 protein alone had either little or no effect on the
activities of ORF61, ORF10 and gE promoters.The delays in IE4, IE62,
IE63 and gE synthesis may reﬂect a need for synergistic effects of
ORF11 with other viral proteins to achieve the usual kinetics and
levels of expression of key VZV proteins. It is also possible that ORF11
has a function related to virus entry and uncoating or virion assembly.
Our experiments demonstrate thatORF11 is anRNAbindingprotein,
making ORF11 the third of the UL47 homologues in alphaherpesviruses
known to exhibit RNA binding capacity. RNA binding proteins are
important in many aspects of cellular biology, especially in the
regulation of gene expression where they are involved in every stage
and are also often important for viral effects on the protein expression
proﬁle of the host cell to produce anenvironment that supports efﬁcient
viral replication (Sandri-Goldin, 2004). Given its capacity to bind RNAs,
the ORF11 protein could also be involved in the post-transcriptional
control of RNA metabolism, as suggested for other cellular or viral-
encoded RNA binding proteins. Moreover, HSV-1 UL47 has been
reported to bind at least two viral transcripts that are packaged into
virions and these packaged mRNAs can be expressed in newly infected
cells (Sciortino et al., 2001, 2002). Whether VZV virions contain viral
mRNAs has not been investigated, but if so, ORF11 could be involved in
their virion incorporation and delivery into newly infected cells,
promoting the efﬁcient initiation of infection.
We demonstrated that ORF11 N-terminus is required for its RNA
binding function but the C-terminus is not, and that an arginine-rich
motif within the ORF11 RNA binding domain was essential for the RNA
binding function. We did not test whether the central region of the
ORF11 protein was involved in RNA binding but we note that the RNA
binding domains of HSV-1 and BHV-1 UL47 are located in the N-
terminus. The arginine-rich motif of ORF11 is partially conserved in
HSV-1 UL47 protein but it is not required for RNA interactions
(Verhagen et al., 2006a), suggesting that ORF11 and HSV-1 UL47
achieveRNAbindingbya relatedbut not identical process. Nevertheless,
the fact that an arginine-richmotif in the ORF11 proteinmediates direct
binding to RNA is consistentwith the overall role of suchmotifs in UL47
and a number of other viral RNA binding proteins, such as HIV-Rev,
human cytomegalovirus (hCMV) UL69 and Epstein-Barr virus (EBV)
EB2 (Donnelly et al., 2007; Hiriart et al., 2003; Toth et al., 2006; Truant
and Cullen, 1999; Weiss and Narayana, 1998; Zapp et al., 1991).
The evaluation of VZV recombinants that had a deletion or
substitutions altering the ORF11 RNA binding domain as mapped by
ORF11 mutagenesis in plasmid constructs showed no impairment ingrowth as compared to POKA in cultured cells; this ﬁnding was
predicted since ORF11 protein is dispensable for VZV replication in
vitro (Che et al., 2008). When the growth of POKA11-Nd and POKA11-
Ns was assessed in human skin xenografts in SCID mice in vivo,
deleting or disrupting the ORF11 RNA binding domain also had no
effect on replication when compared to POKA, indicating that ORF11
RNA binding capacity is either not required or can be fully
compensated for during VZV infection of differentiated human skin
cells in vivo.
We have noted that the sizes of the ORF11 reiterations differed
between the POKA11-Nd, POKA11-Ns and POKA recombinants. These
differences can be explained by the fact that these regions are difﬁcult to
clone and the size of the reiterations often differs from the template
(Davison and Scott, 1986). The VZV genome containsﬁve tandemdirect
repeats of short G+C-rich sequences, three of which are located within
open reading frames, includingORF11, ORF14 andORF22, and appear to
encode repeated amino acid residues. Similar polypetide-encoding
reiterations are found in other herpesviruses (McGeoch et al., 1985,
1988; Rixon and McGeoch, 1984). However, whether differences in the
repeated amino acid sequences alter the function of the protein is not
known. Inour experiments, theORF11mutantsdidnotdiffer fromPOKA
in their growth characteristics, suggesting that the variable sizes of the
repeat regions in ORF11 did not affect VZV replication in vitro and in
human skin in vivo.
In summary, this study showed that VZV ORF11 encodes a multi-
functional protein. ORF11 is a structural component of the tegument.
ORF11 contribute to the regulation of essential VZV genes in cultured
cells by an as yet undeﬁned mechanism and has the capacity to bind
viral and cellular gene transcripts. The evidence that disrupting the RNA
binding function of ORF11 did not alter VZV skin infection togetherwith
the ﬁnding that ORF11 protein is required for normal levels of IE and gE
protein expression in vitro, suggests that the impaired VZV growth in
skin in the absence of ORF11 may be explained by these effects on the
kinetics of viral protein synthesis or a possible function in virus entry
and uncoating or assembly rather than the lack of functions related to its
RNA binding capacity.
Materials and methods
Generation of antiserum to ORF11
To generate an ORF11-speciﬁc antiserum, ORF11 N-terminal was
ampliﬁed by PCRwith primers P1 and P2 (Table 1) using PfuUltraTMHF
DNA polymerase (Stratagene, La Jolla, CA) and the VZV cosmid
pvFsp73 as a template (Niizuma et al., 2003). The PCR product was
inserted into pGEX-2 T vector (GE Healthcare Bio-Sciences Corp.,
Piscataway, NJ) to yield the expression construct pORF11N-GST. GST-
tagged protein was puriﬁed using a Glutathione Sepharose 4B
MicroSpin column (GE Healthcare, Bio-Sciences Corp., Piscataway,
NJ). Rabbit preimmune serum was obtained and anti-ORF11 serum
(Ab11)was collected at day 77 after ﬁve immunizations with the GST-
ORF11 protein (Josman LLCTM, Inc., CA).
Western blot
POKA-infected melanoma cells were harvested after 48 h infection
and whole cell lysates were prepared with radioimmunoprecipitation
assay (RIPA) buffer as described previously (Che et al., 2006). Cell
lysate was separated by SDS-polyacrylamide gel electrophoresis
(PAGE), electro-transferred onto immobilon-polyvinylidene ﬂuoride
(PVDF)membranes (Millipore, Bedford, MA) and reacted overnight at
4 °C with Ab11 (1:20,000 dilution). Immunoblot of the same protein
extracts was also analyzed by using anti-ORF4 polyclonal antibody
(kindly provided by Dr. Kinchington, University of Pittsburgh, PA) as a
loading control for viral protein.
Table 1
Primer sequences and their VZV genome localization.
































IE63 RT GACGCAGTGCTTACGCGC 111035–111052
*Portions of sequences shown in bold indicate restriction enzymes sites. The underlined
portions contain the introduced or mutated VZV sequence.
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using the Nuclear Extract Kit (ActiveMotif, Carlsbad, CA) and followed
the manufacturer’s instructions. For the comparison of VZV IE and late
protein expression, 1×106 melanoma cells were seeded per well in 6-
well plates 1 day before infection. Cells were infected with log10 4.0
plaque forming units (PFU) of POKA or POKAΔ11 per well. Equivalent
amounts of cell lysates extracted from infected cells over a time
course of 1-, 2-, 3- and 4-day post-infection were resolved on SDS-
PAGE followed by Western blot analysis with rabbit polyclonal
antibodies against IE4, IE63 (kindly provided by Dr. Kinchington)
and IE62 (kindly provided by Dr. Ruyechan, University of Buffalo, NY),
respectively, or with mouse monoclonal antibody against gE
(MAB8612, Millipore Biosciences, Temecula, CA).
Plasmid construction
The full-lengthORF11 sequencewas generatedbyPCRusingprimers
P3 and P4,with the pvFsp73 cosmid as a template. The PCR product was
cloned into the pcDNA3.1 vector (Invitrogen, Carlsbad, CA) to obtain an
ORF11 expression plasmid, pCMV11. The IE62 expression plasmid
pCMV62 and luciferase reporter plasmids pGL3-ORF61, pGL3-ORF10
and pGL3-gE were reported previously (Berarducci et al., 2007; Che et
al., 2007; Wang et al., 2009).
Plasmids pORF11/1–261-GST, pORF11/16–261-GST, pORF11/116–
261-GST and pORF11/191–261-GST, expressing residues 1–261, 16–
261, 116–261, 191–261, respectively, as GST fusion proteins, were
generated by PCR with primers, P1 and P2; P7 and P2; P8 and P2; P9
and P2; the cosmid pvFsp73 was used as the template (Table 1).
Plasmids pORF11/1–122-GST, pORF11/16–122, and pORF11/1–22,
expressing ORF11 amino acid residues 1–122, 16–122, and 1–22,
respectively, were constructed using cosmid pvFsp73 as a template;
PCR was done with three pairs of primers, including P1 and P10; P7and P10; P1 and P11. The plasmid pORF11N/ST1-GST, which
expresses the ORF11 N-terminal 1–122 aa with the arginine-rich
motif RRQSRRQR mutated to AAQSAAQA as a GST fusion protein (the
underlined residues show the mutated amino acids) was generated
through four PCRs. The ﬁrst PCR was done with the plasmid pORF11/
1–261-GST as a template and primers P12 and P10, the second PCR
was synthesized by using the ﬁrst PCR product as a template and
primers P13 and P10, the third PCR was done using the second PCR
product as a template and primers P14 and P10, and the last PCR was
obtained by using the third PCR product as a template and primers
P15 and P10. Plasmid pORF11/ST2-GST, expressing the ORF11 N-
terminus with mutation of the ﬁrst two arginines in the arginine-rich
motif to alanines, was generated with pORF11N/ST1-GST plasmid as a
template and primers P16 and P10. Plasmid pORF11C-GST, in which
ORF11 C-terminal tagged with GST, was constructed by PCR with the
pair of primers P5 and P6 and the cosmid pvFsp73 as a template. The
resulting PCR fragments were inserted into SmalI-cut pGEX-2T vector.
Reporter gene assays, cryo-immuno electron microscopy and confocal
microscopy
Reporter gene assays and cryo-immuno EM samples were
prepared as described previously (Che et al., 2007, 2008). For confocal
microscopy, human embryonic lung ﬁbroblasts (HELF) were ﬁxed
with 4% formaldehyde at 10 and 24 h after VZV infection. After
blocking with 1% ﬁsh gelatin for 1 h at RT, cells were incubated with a
murine monoclonal anti-IE62 antibody (kindly provided by Dr.
Ruyechan) and Ab11, or murine monoclonal anti-gE for 1 h at RT.
Cells were washed and incubated for 1 h at RT with ﬂuorescein
isothiocyanate-labeled anti-rabbit and Texas Red-labeled anti-mouse
secondary antibodies (Jackson ImmunoResearch, Inc.). Cell nuclei
were counterstained with Hoechst 22358 (Invitrogen, Carlsbad, CA).
Analysis was performed with a Leica TCSSP2 confocal laser scanning
microscopy (Heidelberg, Germany).
RNA immunoprecipitation and detection using RT-PCR
Cells were lysed using RNase-free lysis buffer [50 mM Tris (pH
7.6), 150 mM NaCl, 2.5 mMMgCl, 0.1% NP-40, and protease inhibitor]
and incubated at 4 °C for 10 min. Cells were then sonicated for 30 s
and centrifuged at 4 °C for 10 min at 2851 RCF. The supernatant was
collected in a fresh tube and RNasin (Invitrogen, Carlsbad, CA) was
added at 1 U/μl. Immunoprecipitation was performed with 400 μl of
cell extracts and 5 μl of Ab11 or anti-ORF47 antibody. After the ﬁnal
wash, the beads were resuspended in 300 μl of lysis buffer and
extracted once with phenol and once with phenol-chloroform (pH
4.6). The extracted nucleic acid was ethanol precipitated and
dissolved in 100 μl elution buffer (1 mM EDTA, Applied Biosystems/
Ambion, Austin, TX). After treatmentwith 10 units of DNase I (Applied
Biosystems/Ambion, Austin, TX) for 1 h at 37 °C, each sample was
extracted by phenol-chloroform (pH 4.6), precipitated by ethanol, and
resuspended in 40 μl RNase-free water. RT-PCR was done with the
samples puriﬁed by RNA immunoprecipitation. cDNA was synthe-
sized using an oligo(dT)-containing adaptor primer (Table 1), PCR
was then done with an ORF63 gene-speciﬁc primer and an adaptor
primer. The resulting PCR product was cloned and sequenced.
Synthesis of RNA probes and Northwestern blot
PCR products corresponding to VZV IE, early and late genes, and to
cellular gene α-actin, were cloned under the control of a T7 promoter
(Che et al., 2006). 1 μg of plasmid DNA was linearized and incubated
for 1 h at 37 °C in a ﬁnal reaction volume of 20 μl, containing 1 × T7
RNA polymerase reaction buffer, 10 mM ATP, CTP, and GTP, 2 μl of T7
RNA polymerase (Applied Biosystems/Ambion, Austin, TX); and 5 μl of
[α-32P]-UTP (3,000 Ci/mmol) (GE Healthcare, Bio-Sciences Corp.,
165X. Che et al. / Virology 412 (2011) 156–166Piscataway, NJ). After addition of 1 unit of DNase I, the radio-labeled
probe was puriﬁed by Illustra™ MicroSpin™ G-25 Column (GE
Healthcare, Bio-Sciences Corp., Piscataway, NJ). Each probe was
prepared in parallel with two reactions, in which one included non-
radioactive labeled UTP and the other contained [α-32P]-UTP. After
puriﬁcation, 5 ul of non-radio-labeled probe was loaded on an
ethidium bromide-containing agrose gel to insure the probe quality.
For Northwestern blots, puriﬁed proteins were separated on a 10%
denaturing polyacrylamide gel and transferred to a nitrocellulose
membrane. The transferred proteins were renatured in 10 mM Tris
(pH 7.6), 50 mM NaCl, 1 mM EDTA, 0.1% NP-40, 0.02% Ficoll, 0.02%
polyvinylpyrrolidone, and 0.02% bovine serum albumin overnight at
4 °C and then pre-hybridized for 1 h at RT in the same buffer containing
0.05 mg/ml Saccharomyces cerevisiae tRNA (Applied Biosystems/
Ambion, Austin, TX). Hybridization was carried out with the same
buffer containingα-32P labeled RNA probe for 4 h at room temperature.
Blots were washed after hybridization and exposed to X-ray ﬁlm.
Recombinant viruses
Several steps were involved in generating VZV recombinant viruses
in which the RNA binding domain of ORF11 was either deleted or
disrupted. The ﬁrst step was to obtain two SacI–EcoRI fragments
corresponding to POKA genome nt 11436 to 14667 (Gomi et al., 2002).
To delete the ORF11 N-terminal 100 residues, two fragments were
ampliﬁed by PCR with primers P17 and P18 and primers P19 and P20.
The resulting PCR products were inserted by triple ligation into the
pCRII-TOPO vector (Invitrogen, Carlsbad, CA). To make the fragment
containing a ﬁve-alanine substitution in the ORF11 arginine-rich motif,
PCRwas generatedwith two pairs of primers, P18 and P21, and P20 and
P22, the two resulting PCR products were ligated into the pCRII-TOPO
vector through SacI and EcoRI restriction sites. The second step
eliminated a single NheI site from SacI–EcoRI fragment without
changing any gene codons. The four primers used were P23 plus P24
and P25 plus P26. The third step was to generate a SacI-NheI fragment
which covers the VZV genome from nt 11436 to 19129 by ligating the
SacI/EcoRI fragment to a pT7Blue-3 plasmid (New England Biolabs,
Beverly, Mass) which contained a 6.7-kb NheI-NheI fragment
corresponding to nt 12339 to 19129, digested by SacI and EcoRI. In
the ﬁnal step, two SacI-NheI fragments, one deleting the ORF11 N-
terminus and the other mutating its RNA binding motif, were used to
replace the SacI-NheI fragment in the cosmid pvFsp73. Recombinant
viruses were isolated from humanmelanoma cells transfected with the
mutated pvFsp73 cosmid and three intact cosmids, pvSpe14, pvPme2,
and pvSpe23. Mutations were conﬁrmed by sequencing. Viruses were
propagated in HELF for infection of SCIDhu mouse xenografts and the
replication kinetics and peak titers of recombinant viruses were
assessed by infectious focus assay (Moffat et al., 1995).
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